Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Artículo científico (JournalArticle)

Metabolomic profile of cancer stem cell‐derived exosomes from patients with malignant melanoma

  • Palacios Ferrer, José Luis
  • García Ortega, María Belén
  • Gallardo Gomez, María
  • García, María Ángel
  • Díaz, Caridad
  • Boulaiz, Houria
  • Valdivia, Javier
  • Jurado, José Miguel
  • Almazán Fernández, Francisco M.
  • Arias Santiago, Salvador
  • Amezcua, Víctor
  • Peinado, Héctor
  • Vicente, Francisca
  • Pérez del Palacio, José
  • Marchal, Juan A.
Malignant melanoma (MM) is the most aggressive and life-threatening form of skin cancer. It is characterized by an extraordinary metastasis capacity and chemotherapy resistance, mainly due to melanoma cancer stem cells (CSCs). To date, there are no suitable clinical diagnostic, prognostic or predictive biomarkers for this neoplasia. Therefore, there is an urgent need for new MM biomarkers that enable early diagnosis and effective disease monitoring. Exosomes represent a novel source of biomarkers since they can be easily isolated from different body fluids. In this work, a primary patient-derived MM cell line enriched in CSCs was characterized by assessing the expression of specific markers and their stem-like properties. Exosomes derived from CSCs and serums from patients with MM were characterized, and their metabolomic profile was analysed by high-resolution mass spectrometry (HRMS) following an untargeted approach and applying univariate and multivariate statistical analyses. The aim of this study was to search potential biomarkers for the diagnosis of this disease. Our results showed significant metabolomic differences in exosomes derived from MM CSCs compared with those from differentiated tumour cells and also in serum-derived exosomes from patients with MM compared to those from healthy controls. Interestingly, we identified similarities between structural lipids differentially expressed in CSC-derived exosomes and those derived from patients with MM such as the glycerophosphocholine PC 16:0/0:0. To our knowledge, this is the first metabolomic-based study aimed at characterizing exosomes derived from melanoma CSCs and patients' serum in order to identify potential biomarkers for MM diagnosis. We conclude that metabolomic characterization of CSC-derived exosomes sets an open door to the discovery of clinically useful biomarkers in this neoplasia, Ministerio de Ciencia, Innovación y Universidades | Ref. FPU15/03682, Ministerio de Ciencia, Innovación y Universidades | Ref. FPU15/02350, Ministerio de Ciencia, Innovación y Universidades | Ref. MAT2015-62644.C2.2.R, Ministerio de Ciencia, Innovación y Universidades | Ref. RTI2018-101309-BC2, Instituto de Salud Carlos III | Ref. PIE16-00045, Junta de Andalucía | Ref. UCE-PP2017-3, European Commission | Ref. SOMM17/6109/UGR, Universidad de Granada | Ref. CMC-CTS963
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Serum methylation of GALNT9, UPF3A, WARS, and LDB2 as noninvasive biomarkers for the early detection of colorectal cancer and advanced adenomas

  • Gallardo-Gómez, María
  • Rodríguez-Girondo, Mar
  • Planell, Núria
  • Moran, S|||0000-0003-4192-8983
  • Bujanda, Luis|||0000-0002-4353-9968
  • Etxart, Ane
  • Castells, Antoni|||0000-0001-8431-2033
  • Balaguer, Francesc|||0000-0002-0206-0539
  • Jover, Rodrigo
  • Esteller, M|||0000-0003-4490-6093
  • Cubiella, Joaquín
  • Gómez-Cabrero, David
  • De Chiara, Loretta
Background: Early detection has proven to be the most effective strategy to reduce the incidence and mortality of colorectal cancer (CRC). Nevertheless, most current screening programs suffer from low participation rates. A blood test may improve both the adherence to screening and the selection to colonoscopy. In this study, we conducted a serum-based discovery and validation of cfDNA methylation biomarkers for CRC screening in a multicenter cohort of 433 serum samples including healthy controls, benign pathologies, advanced adenomas (AA), and CRC. Results: First, we performed an epigenome-wide methylation analysis with the MethylationEPIC array using a sample pooling approach, followed by a robust prioritization of candidate biomarkers for the detection of advanced neoplasia (AN: AA and CRC). Then, candidate biomarkers were validated by pyrosequencing in independent individual cfDNA samples. We report GALNT9, UPF3A, WARS, and LDB2 as new noninvasive biomarkers for the early detection of AN. The combination of GALNT9/UPF3A by logistic regression discriminated AN with 78.8% sensitivity and 100% specificity, outperforming the commonly used fecal immunochemical test and the methylated SEPT9 blood test. Conclusions: Overall, this study highlights the utility of cfDNA methylation for CRC screening. Our results suggest that the combination methylated GALNT9/UPF3A has the potential to serve as a highly specific and sensitive blood-based test for screening and early detection of CRC.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Serum DNA methylome of the colorectal cancer serrated pathway enables non-invasive detection

  • Gallardo-Gómez, María
  • Costas-Ríos, Lara
  • García-Prieto, Carlos A.|||0000-0001-5021-6916
  • Álvarez-Rodríguez, Lara
  • Bujanda, Luis|||0000-0002-4353-9968
  • Barrero, Maialen
  • Castells, Antoni|||0000-0001-8431-2033
  • Balaguer, Francesc|||0000-0002-0206-0539
  • Jover, Rodrigo
  • Esteller, M.|||0000-0003-4490-6093
  • Tardío Baiges, Antoni
  • González-Carreró Fojón, Joaquín
  • Cubiella, Joaquín|||0000-0002-9994-4831
  • De Chiara, Loretta
The clinical relevance of the colorectal cancer serrated pathway is evident, but the screening of serrated lesions remains challenging. We aimed to characterize the serum methylome of the serrated pathway and to evaluate circulating cell-free DNA (cfDNA) methylomes as a potential source of biomarkers for the non-invasive detection of serrated lesions. We collected serum samples from individuals with serrated adenocarcinoma (SAC), traditional serrated adenomas, sessile serrated lesions, hyperplastic polyps and individuals with no colorectal findings. First, we quantified cfDNA methylation with the MethylationEPIC array. Then, we compared the methylation profiles with tissue and serum datasets. Finally, we evaluated the utility of serum cfDNA methylation biomarkers. We identified a differential methylation profile able to distinguish high-risk serrated lesions from no serrated neoplasia, showing concordance with tissue methylation from SAC and sessile serrated lesions. Serum methylation profiles are pathway-specific, clearly separating serrated lesions from conventional adenomas. The combination of ninjurin 2 (NINJ2) and glutamate-rich 1 (ERICH1) methylation discriminated high-risk serrated lesions and SAC with 91.4% sensitivity (64.4% specificity), while zinc finger protein 718 (ZNF718) methylation reported 100% sensitivity for the detection of SAC (96% specificity). This is the first study exploring the serum methylome of serrated lesions. Differential methylation of cfDNA can be used for the non-invasive detection of colorectal serrated lesions.